Remifentanil for Sedation of Patients With Traumatic Brain Injury (TBI)

Completed

• Conditions: Traumatic Brain Injury
• Interventions: Drug: Remifentanil

• Registration Number: NCT02049320
• Lead Sponsor: Joseph D. Tobias

Brief Summary

This is a descriptive retrospective study designed to measure the efficacy of remifentanil sedation and the ability to perform frequent neurological examinations of patients with traumatic brain injuries.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-07
• Study First Submitted: 2014-01-13
• Study First Submitted QC: 2014-01-28
• Study First Posted: 2014-01-30
• Primary Completion: 2016-05
• Study Completion: 2016-05
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-31
• Last Update Posted: 2017-02-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

• Patients previously admitted to the hospital presenting with traumatic brain injury (TBI)
• Patients who have undergone sedation after presenting with TBI

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Remifentanil	Remifentanil	Patients sedated using Remifentanil

Primary Outcome Measures

Name	Time	Method
Depth of Sedation	Every 24 hrs until discharged from the PICU, up to 1 month.	Sedation scores will be assessed.

Trial Locations

Locations (1)

Nationwide Children's Hospital; 🇺🇸 Columbus, Ohio, United States